Ann: Trading Halt, page-7

Here you go my friends,
Dimerix Bioscience is a public unlisted clinical stage drug discovery and development company, based in Melbourne. Dimerix’s lead clinical program is a Phase 2 study in Chronic Kidney Disease, DMX-200. This study has repurposing of existing molecules at its core, and upon successful results from this study, Dimerix intends to pursue the pathway of registration of a product for an orphan indication. The study has been initiated at the Austin Hospital under the supervision of Professor Power, and is currently recruiting patients.